(Reuters) – AstraZeneca said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash.
The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D’Souza)
